2011
DOI: 10.1590/s1807-59322011000100018
|View full text |Cite
|
Sign up to set email alerts
|

Recombinant factor VIIA is associated with an improved 24-hour survival without an improvement in inpatient survival in massively transfused civilian trauma patients

Abstract: OBJECTIVE:To determine whether recombinant factor VIIa (rFVIIa) is associated with increased survival and/or thromboembolic complications.INTRODUCTION:Uncontrollable hemorrhage is the main cause of early mortality in trauma. rFVIIa has been suggested for the management of refractory hemorrhage. However, there is conflicting evidence about the survival benefit of rFVIIa in trauma. Furthermore, recent reports have raised concerns about increased thromboembolic events with rFVIIa use.METHODS:Consecutive massively… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

3
2
0

Year Published

2012
2012
2020
2020

Publication Types

Select...
8
2

Relationship

1
9

Authors

Journals

citations
Cited by 10 publications
(5 citation statements)
references
References 29 publications
3
2
0
Order By: Relevance
“…In contrast, there were no significant effects in the penetrating trauma patients, although trends towards reduced RBC requirements and fewer massive transfusions were observed [ 716 ]. Similar results and trends were observed in other retrospective studies and case reports [ 717 719 ]. A further randomised clinical trial aimed to evaluate rFVIIa as an adjunct to direct haemostasis in major trauma patients who bled four to eight RBC units within 12 h of injury and were still bleeding despite strict DCR and operative management.…”
Section: Resultssupporting
confidence: 91%
“…In contrast, there were no significant effects in the penetrating trauma patients, although trends towards reduced RBC requirements and fewer massive transfusions were observed [ 716 ]. Similar results and trends were observed in other retrospective studies and case reports [ 717 719 ]. A further randomised clinical trial aimed to evaluate rFVIIa as an adjunct to direct haemostasis in major trauma patients who bled four to eight RBC units within 12 h of injury and were still bleeding despite strict DCR and operative management.…”
Section: Resultssupporting
confidence: 91%
“…In contrast, there were no significant effects in the penetrating trauma patients in this study, although trends towards reduced RBC requirements and fewer massive transfusions were observed. Similar results and trends were observed in other retrospective studies and case reports [ 645 647 ]. A further randomised clinical trial [ 648 ] aimed to evaluate rFVIIa as an adjunct to direct haemostasis in major trauma patients who bled four to eight RBC units within 12 h of injury and were still bleeding despite strict damage control resuscitation and operative management.…”
Section: Resultssupporting
confidence: 91%
“…In contrast, there were no significant effects in the penetrating trauma patients in this study, although trends toward reduced RBC requirements and fewer massive transfusions were observed. Similar results and trends were observed in other retrospective studies and case reports [ 508 - 510 ]. A further randomised clinical trial [ 511 ] aimed to evaluate rFVIIa as an adjunct to direct haemostasis in major trauma patients who bled four to eight RBC units within 12 h of injury and were still bleeding despite strict damage control resuscitation and operative management.…”
Section: Resultssupporting
confidence: 91%